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Background
The 2020 COVID-19 pandemic has stunned the world,
financial markets, and healthcare systems. Researchers are
rushing to identify effective treatments while maintaining
rigorous adherence to the scientific method. Clinicians are
doing their best to provide evidence-based care in a setting
of very little good evidence. To date, no effective treat-
ments exist for COVID-19 management. Unfortunately,
traditional and social media coupled with world leader
commentary have led some to believe hydroxychloroquine
offers a bona fide cure and even prevention. The purpose
of this commentary is to review the medical literature
related to hydroxychloroquine building on knowledge over
the past 17 years since the 2003 SARS-CoV epidemic.
Main text
Pre-clinical evidence
Hydroxychloroquine has been used for the treatment of mal-
aria since 1955 and is approved for the treatment of rheuma-
toid arthritis and lupus. Currently, the potential mechanism
of action for hydroxychloroquine’s effect on SARS-CoV1
and SARS-CoV2 is not fully known. It is hypothesized that
increases in endosomal pH may inhibit viral fusion and repli-
cation with interference in ACE2 receptor glycosylation or
Sigma-1 receptor [1, 2]. Chloroquine and hydroxychloro-
quine seem effective in killing SARS-CoV in vitro [1, 3]. Re-
cent reports show it also may be effective at killing SARS-
CoV-2-infected cells in vitro [4]. Unfortunately, effective
treatments in vitro frequently do not translate in vivo and
the efficacy of hydroxychloroquine is yet to be determined.
Pre-clinical animal (in vivo) models more accurately
model human safety and efficacy and enable better pre-
diction of translational failure into humans. Chloroquine
was not found to be efficacious in mouse models in-
fected with SARS-CoV despite multiple dosing schedules
and treatment routes [5]. To date, no pre-clinical studies
have evaluated the efficacy of hydroxychloroquine in the
current SARS-CoV-2 pandemic.
Current evidence
A recent article published in Chinese found no benefit with
chloroquine in a 1:1 randomized trial with 30 patients [6].
As yet there are no published randomized controlled trials
of hydroxycholoroquine in SARS-CoV-1 or 2. Recently, a
publication by Gautret et al. has been touted by non-
medical public figures as proof of a cure for COVID-19 [7].
This has led to significant interest in news outlets, social
media, and the general public. This study was a non-
randomized, non-blinded, open label, and underpowered
trial. Given these limitations, it does not meet the rigor for
evaluation of scientific efficacy. To illustrate, Gautret et al.
treated 26 patients with hydroxychloroquine (six received
concomitant azithromycin) that met study inclusion cri-
teria. The control group was subsequently made up of 16
patients who did not meet the study inclusion criteria. The
primary outcome was viral load, defined by a cycle time
(CT) threshold of 35. CT is the number of reverse tran-
scription PCR cycles necessary to detect the presence of
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viral RNA. A lower CT is associated with increased viral
load. A CT greater than or equal to 35 was deemed as a
negative viral titer. It was unclear whether this threshold
was set a priori or post hoc. After enrollment of 42 patients,
an interim analysis was conducted and published. A critical
result was the exclusion of six patients from the treatment
arm. One died, three decompensated requiring transfer to
the ICU, one withdrew from the study due to drug-related
complications, and one was lost to follow-up. These pa-
tients were excluded by the authors from final analysis. The
authors then compared viral titers from 20 patients that re-
ceived hydroxychloroquine (or combination with azithro-
mycin) with the 16 control patients that were ineligible to
receive hydroxychloroquine. In unadjusted analyses, the au-
thors identified significantly reduced viral titers in the
hydroxychloroquine arm. No comment was made regard-
ing the higher mortality, complication, and adverse event
rate in the hydroxychloroquine group.
Excluding those who did poorly with hydroxychloro-
quine is a biased analysis that impacts the potential val-
idity of the study. Reincorporation of the 6 patients into
the statistical analysis would have significantly changed
the results of this study. In the hydroxychloroquine
group, 5 of 26 (19.2%) of COVID-19 patients suffered
death, medical deterioration, or adverse event compared
with 0 (0%) in the control arm (Barnard’s test: p = 0.07)
with a number needed to harm (NNH) of 5.2.
Conclusion
Until data from randomized controlled trials are available,
we suggest caution utilizing hydroxychloroquine off label
for patients with COVID-19. Reports of overdoses are
now occurring. There are currently no evidence support-
ing hydroxychloroquine as prophylaxis, but unfortunately
these data are being extrapolated to the indication poten-
tially resulting in drug shortages for patients with rheum-
atic diseases who require this medication. Furthermore,
we caution medical and world leaders against premature
comments of treatment efficacy during the COVID-19
pandemic. Such comments may exacerbate shortages for
patients reliant on these medications or cause harm due
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